The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma

This video episode follows the journey of a 55-year-old female tech CEO with multiple myeloma, highlighting her treatments, relapse challenges, and transition to ide-cel, supported by her active lifestyle and strong support network.

Medical experts examine the factors that make Sarah an ideal candidate for CAR-T therapy in the second-line setting, focusing on how her age, fitness, and early relapse influence treatment decisions and exploring alternative options.

This video episode explores data supporting ide-cel in the second-line setting for multiple myeloma, highlighting key findings from the KarMMa and KarMMa-3 trials, comparisons to other options, and clinical experiences regarding efficacy, quality of life benefits, and implementation challenges.

This video episode examines decision-making between CAR-T therapy and novel agents in the second-line setting, scenarios for preferring alternative therapies, and treatment strategies following progression after ide-cel, emphasizing the impact of prior CAR-T therapy on subsequent choices.

This video episode highlights the journey of a 72-year-old retired science teacher with multiple myeloma, covering his treatments, relapse, management of comorbidities, and transition to cilta-cel, supported by his active and healthy wife.

This video episode explores treatment decisions for second-line therapy in a patient with age and comorbidities, reviews cilta-cel data from the CARTITUDE trials, and discusses clinical experience with cilta-cel, emphasizing efficacy, quality of life, and adaptations for complex patient profiles.

This video episode compares ide-cel and cilta-cel for patient selection, examining specific characteristics, efficacy and safety profiles, and their influence on treatment decisions across diverse patient groups.